Petra Gorombei is an Investment Professional at Vensana Capital. Petra brings extensive experience overseeing large-scale global clinical trials and clinical operations to Vensana. Prior to joining Vensana, Petra served as Clinical Evidence Director at ZOLL Medical, where she led clinical evidence generation strategies to support new product launches for ZOLL’s cardiac management solutions business. She also spent significant time in the field working with customers and the commercial team, while also supporting due diligence efforts for corporate investments and acquisitions. Petra currently serves as a board observer and is engaged with several portfolio companies including Abrus Bio, Luna Diabetes, Nyra Medical, and Ventaris Surgical, among others. Petra earned a PhD in cancer research from Paris Diderot University and an Executive MBA at Duke University’s Fuqua School of Business.